Results 271 to 280 of about 218,137 (295)
Some of the next articles are maybe not open access.
Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B
Hepatobiliary & Pancreatic Diseases International, 2013The role of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) in persistent HBV infection is controversial. Increasing PD-1 and PD-L1 expression has been found in hepatitis B patients during immune clearance phase, but not in HBV-tolerant patients.
Wen-Jin, Zhang +2 more
openaire +2 more sources
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Expert Opinion on Biological Therapy, 2013Multiple agents targeting the immune "checkpoint" programmed death-1 (PD-1) pathway have demonstrated early evidence of durable clinical activity and an encouraging safety profile in patients with various tumor types, including some cancers, such as non-small-cell lung cancer, historically perceived as non-immunogenic and thus nonresponsive to ...
Omid, Hamid, Richard D, Carvajal
openaire +2 more sources
Programmed Cell Death–Ligand 1 Overexpression in Thyroid Cancer
Endocrine Practice, 2019Programmed cell death-ligand 1 (PD-L1) expression on tumor tissue has been associated with favorable response to anti-programmed cell death-receptor 1/PD-L1 therapy in many human cancers. Studies have reported that PD-L1 is also expressed in thyroid cancer.
Guo-Qiang, Zhang +8 more
openaire +2 more sources
Programmed death-ligand 1 expression in pheochromocytoma
European Urology Supplements, 2017H. Yasuhiro +6 more
openaire +1 more source
European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020
Ümran Kucukgoz Gulec +2 more
exaly
Ümran Kucukgoz Gulec +2 more
exaly